Boston Partners
CORT icon

Boston Partners’s Corcept Therapeutics CORT Stock Holding History

Boston Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-335,941
Closed -$2.18M – 750
2016
Q3 		$2.18M Hold
335,941
– – ﹤0.01% 650
2016
Q2 		$1.83M Buy
+335,941
New +$1.75M ﹤0.01% 654

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Partners's CORT Position: Q4 2016 in Review

Boston Partners sold out of Corcept Therapeutics (CORT) in Q4 2016, closing a stake of 335,941 shares — an estimated $2.18M sold.

Boston Partners first reported a position in CORT in Q2 2016 and held it in 2 quarters. The position peaked at $2.18M in Q3 2016. 135 funds tracked by Wall St. Rank hold CORT as of Q4 2016.

  • Boston Partners reported no remaining Corcept Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Boston Partners sold 335,941 Corcept Therapeutics shares in Q4 2016, an estimated $2.18M.
  • Boston Partners first reported a position in Corcept Therapeutics in Q2 2016 and held it in 2 quarters.
  • Boston Partners's Corcept Therapeutics position peaked at $2.18M in Q3 2016.
  • 135 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2016.

Based on Boston Partners's 13F filing for Q4 2016, filed 6 Feb 2017.